Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 2/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14468358 | 0.95 | MMP13 (0.53) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL14345596 | 0.91 | MMP13 (0.57) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL5425633 | 0.89 | MMP13 (0.55) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL10168058 | 0.89 | MMP13 (0.64) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL14446795 | 0.87 | MMP13 (0.54) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL10167293 | 0.85 | MMP13 (0.64) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL10167869 | 0.84 | MMP13 (0.66) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL5423763 | 0.84 | MMP13 (0.56) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL10166977 | 0.84 | MMP13 (0.59) | MMP13ADAMTS4MMP3MMP8MMP12 | |
| SCHEMBL14446794 | 0.83 | MMP13 (0.54) | MMP13ADAMTS4MMP3MMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | MMP13 38/4885ADAMTS4 1/4885MMP3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.